| BE0115-50MG
| InVivoMAb anti-mouse TIM-3 (CD366)
| 50 mg
| BioXCell
| in vivo TIM-3 neutralization, in vitro TIM-3 block
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0139-100MG
| InVivoMAb anti-mouse/human/rat v-H-Ras
| 100 mg
| BioXCell
| Immunoprecipitation
|
| Rat
| Human, Mouse, Rat
| Request Quotation
| Request
|
| BE0178-1MG
| InVivoMAb anti-mouse MHC class II (I-A)
| 1 mg
| BioXCell
| in vivo blockade of TCR stimulation, Flow cytometr
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0097-100MG
| InVivoMAb recombinant mouse IgG2a Fc
| 100 mg
| BioXCell
|
|
|
|
| Request Quotation
| Request
|
| BE0169-1MG
| InVivoMAb anti-mouse 4-1BB (CD137)
| 1 mg
| BioXCell
| in vivo activation of 4-1BB
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0167-100MG
| InVivoMAb anti-mouse/rat MHC Class II (I-Ek/RT1-D)
| 100 mg
| BioXCell
| in vivo blocking of antigen presentation, Flow cyt
|
| Mouse
| Mouse, Rat
| Request Quotation
| Request
|
| BE0130-100MG
| InVivoMAb polyclonal goat IgG
| 100 mg
| BioXCell
|
|
| Goat
|
| Request Quotation
| Request
|
| BE0119-50MG
| InVivoMAb anti-mouse CD4
| 50 mg
| BioXCell
| in vivo CD4+ T cell depletion
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0112-1MG
| InVivoMAb anti-mouse PD-L2 (B7-DC)
| 1 mg
| BioXCell
| in vivo PD-L2 blockade, in vitro PD-L2 blockade, I
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0127-1MG
| InVivoMAb anti-mouse Delta-like protein 4 (DLL4)
| 1 mg
| BioXCell
| in vivo DLL4 neutralization, in vitro DLL4 neutral
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0147-25MG
| InVivoMAb anti-mouse CD48
| 25 mg
| BioXCell
| in vivo CD48 blockade, in vitro CD48 blocking
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0099-1MG
| InVivoMAb recombinant CTLA-4-Ig (hum/hum)
| 1 mg
| BioXCell
|
|
|
|
| Request Quotation
| Request
|
| BE0173-50MG
| InVivoMAb anti-mouse IL-17A
| 50 mg
| BioXCell
| in vivo IL-17A neutralization
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0089-5MG
| InVivoMAb rat IgG2a isotype control, anti-trinitrophenol
| 5 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0158-5MG
| InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk)
| 5 mg
| BioXCell
| in vivo administration, Flow cytometry
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0166-25MG
| InVivoMAb anti-mouse V?4 TCR
| 25 mg
| BioXCell
| in vivo administration, Flow cytometry
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0146-50MG
| InVivoMAb anti-mouse PD-1 (CD279)
| 50 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0127-25MG
| InVivoMAb anti-mouse Delta-like protein 4 (DLL4)
| 25 mg
| BioXCell
| in vivo DLL4 neutralization, in vitro DLL4 neutral
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0180-50MG
| InVivoMAb anti-mouse MHC Class I (H-2Kd, H-2Dd)
| 50 mg
| BioXCell
| in vivo activation of APCs
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0091-25MG
| InVivoMAb polyclonal Armenian hamster IgG
| 25 mg
| BioXCell
|
|
| Armenian Hamster
|
| Request Quotation
| Request
|
| BE0117-1MG
| InVivoMAb anti-mouse CD8?
| 1 mg
| BioXCell
| in vivo CD8+ T cell depletion, Western blot
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0127-5MG
| InVivoMAb anti-mouse Delta-like protein 4 (DLL4)
| 5 mg
| BioXCell
| in vivo DLL4 neutralization, in vitro DLL4 neutral
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0155-5MG
| InVivoMAb anti-mouse Delta-like protein 1 (DLL1)
| 5 mg
| BioXCell
| in vivo DLL1 neutralization, Flow cytometry
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0130-1MG
| InVivoMAb polyclonal goat IgG
| 1 mg
| BioXCell
|
|
| Goat
|
| Request Quotation
| Request
|
| BE0093-50MG
| InVivoMAb polyclonal mouse IgG
| 50 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| BE0124-50MG
| InVivoMAb anti-mouse CD276 (B7-H3)
| 50 mg
| BioXCell
| in vivo B7-H3 blockade, Flow cytometry
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0111-5MG
| InVivoMAb anti-mouse NKG2D
| 5 mg
| BioXCell
| in vivo NKG2D blockade
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0125-50MG
| InVivoMAb anti-mouse Jagged 2
| 50 mg
| BioXCell
| in vivo Jagged 2 neutralization
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0094-50MG
| InVivoMAb polyclonal rat IgG
| 50 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0110-100MG
| InVivoMAb anti-mouse 4-1BBL (CD137L)
| 100 mg
| BioXCell
| in vivo 4-1BBL blockade, ELISA
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0189-25MG
| InVivoMAb anti-human CD40
| 25 mg
| BioXCell
| in vitro CD40 stimulation, Functional assays, Flow
|
| Mouse
| Human
| Request Quotation
| Request
|
| BE0091-FAB-5MG
| InVivoMAb hamster IgG f(ab')2 fragments
| 5 mg
| BioXCell
|
|
|
|
| Request Quotation
| Request
|
| BE0188-5MG
| InVivoMAb anti-human PD-1 (CD279)
| 5 mg
| BioXCell
| in vitro PD-1 neutralization, in vivo PD-1 blockad
|
| Mouse
| Human
| Request Quotation
| Request
|
| BE0090-5MG
| InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin
| 5 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0097-50MG
| InVivoMAb recombinant mouse IgG2a Fc
| 50 mg
| BioXCell
|
|
|
|
| Request Quotation
| Request
|
| BE0164-50MG
| InVivoMAb anti-mouse CTLA-4 (CD152)
| 50 mg
| BioXCell
| in vivo CTLA-4 neutralization, Western blot
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0095-25MG
| InVivoMAb polyclonal rabbit IgG
| 25 mg
| BioXCell
|
|
| Rabbit
|
| Request Quotation
| Request
|
| BE0165-50MG
| InVivoMAb anti-mouse Nonclassical MHC Class I molecule Qa-1b
| 50 mg
| BioXCell
| Western blot, Immunofluorescence
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0087-50MG
| InVivoMAb polyclonal Syrian hamster IgG
| 50 mg
| BioXCell
|
|
| Syrian Hamster
|
| Request Quotation
| Request
|
| BE0094-1MG
| InVivoMAb polyclonal rat IgG
| 1 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0110-1MG
| InVivoMAb anti-mouse 4-1BBL (CD137L)
| 1 mg
| BioXCell
| in vivo 4-1BBL blockade, ELISA
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0188-100MG
| InVivoMAb anti-human PD-1 (CD279)
| 100 mg
| BioXCell
| in vitro PD-1 neutralization, in vivo PD-1 blockad
|
| Mouse
| Human
| Request Quotation
| Request
|
| BE0123-5MG
| InVivoMAb anti-human/rat/fish AChR
| 5 mg
| BioXCell
| EAMG induction in rats, Immunofluorescence
|
| Rat
| Fish, Human, Rat
| Request Quotation
| Request
|
| BE0167-50MG
| InVivoMAb anti-mouse/rat MHC Class II (I-Ek/RT1-D)
| 50 mg
| BioXCell
| in vivo blocking of antigen presentation, Flow cyt
|
| Mouse
| Mouse, Rat
| Request Quotation
| Request
|
| BE0104-50MG
| InVivoMAb anti-mouse MHC Class I (H-2Kd)
| 50 mg
| BioXCell
| Purification of MHC peptide complexes, in vivo adm
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0143-25MG
| InVivoMAb anti-rat ?-2-Microglobulin
| 25 mg
| BioXCell
| in vitro ?2M blockade
|
| Mouse
| Rat
| Request Quotation
| Request
|
| BE0176-50MG
| InVivoMAb anti-mouse Kappa Immunoglobulin Light Chain
| 50 mg
| BioXCell
| Immunofluorescence
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0131-25MG
| InVivoMAb anti-mouse CTLA-4 (CD152)
| 25 mg
| BioXCell
| in vivo CTLA-4 neutralization, in vitro CTLA-4 neu
|
| Syrian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0096-5MG
| InVivoMAb recombinant human IgG1 Fc
| 5 mg
| BioXCell
|
|
|
|
| Request Quotation
| Request
|
| BE0183-25MG
| InVivoMAb anti-mouse Ter-119
| 25 mg
| BioXCell
| in vivo administration, in vitro erythrocyte negat
|
| Rat
| Mouse
| Request Quotation
| Request
|